Moore v. Regents of the University of California

Arima Genomics is Enabling Single Cell 3D Genome Exploration of the Human Brain, One Cell at a Time

Retrieved on: 
Wednesday, January 4, 2023

Arima Genomics, Inc., the leader in 3D genomics, today announced that it is launching into the world of single-cell analyses by enabling a team of researchers to map the 3D genome of the human brain, cell by cell.

Key Points: 
  • Arima Genomics, Inc., the leader in 3D genomics, today announced that it is launching into the world of single-cell analyses by enabling a team of researchers to map the 3D genome of the human brain, cell by cell.
  • The research spans several multi-omic technologies, including 3D genomics, DNA methylation and RNA expression, to describe brain cells in unprecedented molecular detail – to classify brain cells into precise subtypes and pinpoint the location of each brain cell.
  • Specifically, they will use the Arima Genomics kits as part of their single-nucleus methyl-3C sequencing ​(sn-m3C-Seq) workflow, which enables concurrent cell-by-cell interrogation of the methylation state and 3D chromatin organization of the genome.
  • We are just beginning to understand its potential to reveal new biology in the brain,” said Anthony Schmitt, PhD, Senior Vice President of Science at Arima Genomics.

PACT Pharma Reports Data From First Clinical Study Using CRISPR to Substitute a Gene in Patients' Immune Cells to Treat Cancer

Retrieved on: 
Thursday, November 10, 2022

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2022 /PRNewswire/ -- PACT Pharma, Inc., a privately held biopharmaceutical company developing transformational personalized neoantigen-specific and off-the-shelf T cell receptor (TCR)-T cell therapies for the eradication of solid tumors, today reported data from the first clinical study using CRISPR gene editing technology to substitute a gene in patients' immune cells to treat cancer. Results from the study, which was conducted with collaborators at nine academic centers using PACT's proprietary platforms, demonstrated early proof-of-concept that a patient's immune system can be reprogrammed to recognize their own cancer. The study findings were the focus of a late breaking oral presentation at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2022), as well as a peer-reviewed paper in Nature that was published in conjunction with SITC 2022.

Key Points: 
  • Every patient's immune system contains T cells that can utilize specific receptors to find and kill cancer cells.
  • Unfortunately, patients often do not have enough of these T cells to mount a complete and effective attack on their cancer.
  • Once infused back into the patient, these engineered T cells redirect the patients' immune system to recognize the patient's own cancer.
  • The study involved researchers using patients' blood samples to directly isolateT cells targeting mutations related to each patient's cancer.

Finding HIV's Sweet Spot

Retrieved on: 
Tuesday, July 5, 2022

SAN FRANCISCO, July 5, 2022 /PRNewswire/ -- HIV researchers have long been trying to identify the specific cells that the virus prefers to infect and hide in. They know that HIV favors a special type of immune cells called memory CD4 T cells. But these cells come in many flavors, and it has been difficult to ascertain exactly what makes one type of memory CD4 T cell more attractive to HIV than another.

Key Points: 
  • Together, the scientists uncovered surprisingly different sugar patterns on different immune cells, and an intriguing interplay between HIV and the sugars coating CD4 Tcells.
  • The work also showcases a new technique for studying individual cells from large populations that could lead to a more detailed picture of cellular diversity.
  • Encouraged by this finding, the scientists next applied CyTOF-Lec to CD4 Tcells that they had first exposed to HIV in the lab.
  • To ensure our work does the greatest good, Gladstone Institutes focuses on conditions with profound medical, economic, and social impactunsolved diseases.

Patent upheld, ERS leadership position in European CRISPR Landscape confirmed

Retrieved on: 
Tuesday, May 31, 2022

DUBLIN, May 31, 2022 /PRNewswire/ -- The Opposition Division of the European patent office has maintained European Patent Number 3401400 over challenges from several groups, reinforcing this strong foundational CRISPR patent in Europe.

Key Points: 
  • DUBLIN, May 31, 2022 /PRNewswire/ -- The Opposition Division of the European patent office has maintained European Patent Number 3401400 over challenges from several groups, reinforcing this strong foundational CRISPR patent in Europe.
  • European Patent 3401400 ('EP400') has withstood formal opposition at the European Patent Office ('EPO') with only minor modifications.The decision by the EPO Opposition Division ('OD') was recently published following lengthy hearings which concluded in February of this year.
  • The patent is jointly owned by ERS founder and Nobel prize winner Dr. Emmanuelle Charpentier, along with the University of Vienna and the University of California (jointly known as the 'CVC' group).
  • Opponents had challenged EP400 at the European Patent Office formally claiming lack of novelty and inventive step and asking the OD to revoke the patent in its entirety.

Patent upheld, ERS leadership position in European CRISPR Landscape confirmed

Retrieved on: 
Tuesday, May 31, 2022

DUBLIN, May 31, 2022 /PRNewswire/ -- The Opposition Division of the European patent office has maintained European Patent Number 3401400 over challenges from several groups, reinforcing this strong foundational CRISPR patent in Europe.

Key Points: 
  • DUBLIN, May 31, 2022 /PRNewswire/ -- The Opposition Division of the European patent office has maintained European Patent Number 3401400 over challenges from several groups, reinforcing this strong foundational CRISPR patent in Europe.
  • European Patent 3401400 ('EP400') has withstood formal opposition at the European Patent Office ('EPO') with only minor modifications.The decision by the EPO Opposition Division ('OD') was recently published following lengthy hearings which concluded in February of this year.
  • The patent is jointly owned by ERS founder and Nobel prize winner Dr. Emmanuelle Charpentier, along with the University of Vienna and the University of California (jointly known as the 'CVC' group).
  • Opponents had challenged EP400 at the European Patent Office formally claiming lack of novelty and inventive step and asking the OD to revoke the patent in its entirety.

Cancer Researchers to Rock Buddy Guy's Legends for One Night Only

Retrieved on: 
Tuesday, April 26, 2022

MILWAUKEE, April 26, 2022 /PRNewswire-PRWeb/ -- The CheckPoints, the Society for Immunotherapy of Cancer's (SITC) house band, return for a performance at Buddy Guy's Legends on June 5. The band features thirteen cancer researchers including Nobel Prize recipient James P. Allison, PhD, Regental Professor and Chair of the Department of Immunology at The University of Texas MD Anderson Cancer Center.

Key Points: 
  • The band features thirteen cancer researchers including Nobel Prize recipient James P. Allison, PhD, Chair of the Department of Immunology at The University of Texas MD Anderson Cancer Center.
  • MILWAUKEE, April 26, 2022 /PRNewswire-PRWeb/ -- The CheckPoints , the Society for Immunotherapy of Cancer 's (SITC) house band, return for a performance at Buddy Guy's Legends on June 5.
  • The band features thirteen cancer researchers including Nobel Prize recipient James P. Allison, PhD, Regental Professor and Chair of the Department of Immunology at The University of Texas MD Anderson Cancer Center.
  • "Inspiring the next generation of cancer immunotherapy researchers has always been one of SITC's main priorities," said SITC President Patrick Hwu, MD.

Immune Response to COVID-19 Vaccine Different with Prior Infection

Retrieved on: 
Tuesday, October 12, 2021

Antibodies produced by the immune system's B cells can quickly recognize a virus, target it for destruction, and prevent infection.

Key Points: 
  • Antibodies produced by the immune system's B cells can quickly recognize a virus, target it for destruction, and prevent infection.
  • While antibodies are more effective at stopping initial infection completely, T cells generally last longer after an initial infection or vaccine and can help quell disease in its early stages, preventing severe symptoms.
  • Distinct subsets of T cells respond differently to infected cells and have different functions within the overall T cell response.
  • However, in those who had previously had a COVID-19 infection, there was little change between the first and second dose of the vaccine.

Chronic Lymphocytic Leukemia (CLL) Pipeline Report 2021: Insights on Approx 60 Companies and Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 28, 2021

This Chronic lymphocytic leukemia - Pipeline Insight, 2021 report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in Chronic lymphocytic leukemia pipeline landscape.

Key Points: 
  • This Chronic lymphocytic leukemia - Pipeline Insight, 2021 report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in Chronic lymphocytic leukemia pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Chronic lymphocytic leukemia R&D.
  • This segment of the Chronic lymphocytic leukemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.
  • This segment of the report provides insights about the different Chronic lymphocytic leukemia drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.